The abstract is read at the publisher; the summary is JClub's.
RSV vaccination in US Medicare fee-for-service nursing home residents was associated with 73% vaccine effectiveness against RSV-associated hospitalization during the first season.
- Why it matters: High-risk nursing home residents need timely real-world effectiveness estimates for RSV vaccines during their initial availability to guide protection strategies.
- What they did: In a retrospective cohort using Medicare claims from September 10, 2023, to March 30, 2024, Cox models compared time to first RSV-associated outcomes between vaccinated and unvaccinated beneficiaries.
- The result: Vaccine effectiveness was 56% for RSV-associated death, 59% for severe RSV-associated outcomes, and 66% for RSV-associated thromboembolic events, with subgroup estimates varying by age and nursing home stay duration.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.